tiprankstipranks
Trending News
More News >
Editas Medicine Inc. (CH:8EM)
:8EM

Editas Medicine (8EM) Price & Analysis

Compare
0 Followers

8EM Stock Chart & Stats

Currently, no data available
Please return soon. This page is being updated.
---

Bulls Say, Bears Say

Bulls Say
Analyst RatingsAnalyst recommends a buy rating, indicating confidence in the company's future prospects and technology.
Financial StabilityEditas ended 1Q25 with $221M in cash and cash equivalents, which Editas expects should provide an operational runway into 2Q27.
Gene Editing TechnologyEditas announced achieving preclinical proof of concept for its in vivo gene editing approach, which supports the potential of its technology.
Bears Say
Financial PerformanceEditas reported a net loss of $0.92 per share in 1Q25 vs. prior estimate of a net loss of $0.55 per share.
Market ExpectationsEditas reported a net loss per share that was larger than the consensus expectations.
Patent UncertaintyThere is increasing uncertainty surrounding the Cas9 patent interference case as it has been remanded back to the PTAB for reconsideration.
---

Financials

Options Prices

Currently, No data available
---

Ownership Overview

0.81%13.84%2.37%70.01%
13.84%
Mutual Funds
2.37% Other Institutional Investors
70.01% Public Companies and Individual Investors

8EM FAQ

What was Editas Medicine Inc.’s price range in the past 12 months?
Currently, no data Available
What is Editas Medicine Inc.’s market cap?
Currently, no data Available
When is Editas Medicine Inc.’s upcoming earnings report date?
Editas Medicine Inc.’s upcoming earnings report date is Jul 30, 2025 which is in 71 days.
    How were Editas Medicine Inc.’s earnings last quarter?
    Editas Medicine Inc. released its earnings results on May 12, 2025. The company reported -$0.768 earnings per share for the quarter, missing the consensus estimate of -$0.471 by -$0.297.
      Is Editas Medicine Inc. overvalued?
      According to Wall Street analysts Editas Medicine Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
        Does Editas Medicine Inc. pay dividends?
        Editas Medicine Inc. does not currently pay dividends.
        What is Editas Medicine Inc.’s EPS estimate?
        Editas Medicine Inc.’s EPS estimate is -0.33.
          How many shares outstanding does Editas Medicine Inc. have?
          Currently, no data Available
          What happened to Editas Medicine Inc.’s price movement after its last earnings report?
          Editas Medicine Inc. reported an EPS of -$0.768 in its last earnings report, missing expectations of -$0.471. Following the earnings report the stock price went same N/A.
            Which hedge fund is a major shareholder of Editas Medicine Inc.?
            Currently, no hedge funds are holding shares in CH:8EM
            ---

            Company Description

            Editas Medicine Inc.

            Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has an early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
            ---

            8EM Stock 12 Month Forecast

            Average Price Target

            $2.60
            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
            Similar Stocks
            Company
            Price & Change
            Follow
            Cellectis SA
            RAPT Therapeutics
            Nkarta
            Neumora Therapeutics, Inc.
            Contineum Therapeutics, Inc. Class A
            Popular Stocks
            ---
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis